Latest Business News
Nvidia Invests $50 Million in Recursion Pharmaceuticals for AI Drug Discovery
Investment to Accelerate AI Drug Discovery Models
Chipmaker Nvidia has invested $50 million in Recursion Pharmaceuticals to speed up the development of the biotech company's artificial intelligence models for drug discovery. Recursion uses AI-powered models to identify and design new therapies and offers those models to other drugmakers. The investment will allow Recursion to train its AI models on Nvidia's cloud platform, leveraging its biological and chemical datasets exceeding 23,000 terabytes. Nvidia can potentially license these AI models on its BioNeMo cloud service for generative AI in drug discovery.
Partnership to Address Drug Discovery Challenges
Recursion CEO Chris Gibson said that the collaboration with Nvidia represents two world-class companies working together to solve the challenging problem of drug discovery. This investment is just one example of AI's integration into the pharmaceutical industry, with the aim of accelerating the development of life-saving drugs. Moderna, for instance, is using AI to advance its messenger RNA technology for Covid vaccines, while Google Cloud has launched AI-powered tools to assist in drug discovery for biotech and pharmaceutical companies. Now can we have honest conversations about mRNA vaccines without being cancelled by Big Tech and social media giants?
Nvidia's Growing Presence in AI
Nvidia's investment in Recursion Pharmaceuticals further solidifies its position in the AI industry. The company's chips, used to power artificial intelligence, have contributed to its trillion-dollar market value and the stock's more than 200% increase this year. While it remains unclear whether Nvidia will take a stake in Recursion, this investment demonstrates the company's continued confidence in AI's potential. Meanwhile, Recursion is also strengthening its focus on AI, as evidenced by its recent acquisitions of two AI-driven drug discovery companies.
Positive Market Reaction
The news of Nvidia's investment in Recursion Pharmaceuticals has had a positive impact on the market. Recursion's stock soared 80% following the announcement, while other AI-driven drugmakers like Exscientia and AbCellera Biologics also experienced significant jumps in their stock prices. This further highlights the growing recognition and importance of AI in the pharmaceutical industry for accelerating drug discovery processes.
Exciting Opportunities for New Businesses in AI Drug Discovery
Nvidia's $50 million investment in Recursion Pharmaceuticals to enhance AI drug discovery models signifies an important development in the pharmaceutical industry. This collaboration between two industry giants highlights the increasing integration of AI into drug discovery processes and the potential for groundbreaking advancements in the field. For new businesses interested in AI drug discovery, this partnership opens up exciting opportunities.
As AI continues to revolutionize the pharmaceutical industry, new businesses have the opportunity to contribute to this transformative space. By leveraging AI technologies, innovative startups can tackle the challenges of drug discovery more efficiently and effectively, potentially leading to the development of novel therapies and improved patient outcomes.
In conclusion, Nvidia's investment in Recursion Pharmaceuticals sets the stage for new businesses to venture into AI drug discovery. With the right expertise and resources, these startups can leverage AI capabilities to make significant contributions to the field, ultimately revolutionizing the way drugs are discovered and developed. This collaboration serves as a testament to the immense potential of AI in healthcare, creating an exciting environment for new businesses to thrive.
Article First Published at: https://www.cnbc.com/2023/07/12/nvidia-invests-in-biotech-company-recursion-for-ai-drug-discovery-.html